


TNFR2 blockade promotes anti-tumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion


A. Debesset, C. Pilon*, S. Meunier*, O. Cuelenaere-Bonizec, W. Richer, A. Thiolat, C. Houpe, M. Ponzo, J. Magnan, J. Caron, P. Caudana, J. Tosello Boari, S. Baulande, N.H. To, B.L. Salomon, E. Piaggio, I. Cascone** and J.L. Cohen**

TNFR2, a validated target in human PDAC



TNFR2 is mainly expressed by Tregs and myeloid cells



TNFR2, a validated target in PDAC mice



Anti-TNFR2 treatment mainly targets activated Treg

Identification of a new combination of treatment

Rational for clinical trial



Anti-TNFR2 + agonist anti-CD40 abolish tumor growth and induce a memory immune response